|
|
Previous Article | Table of Contents | Next Article 
Blood, 1 June 2002, Vol. 99, No. 11, pp. 4087-4093
NEOPLASIA
B-cell chronic lymphocytic leukemia cells express a surface
membrane phenotype of activated, antigen-experienced B
lymphocytes
Rajendra N. Damle,
Fabio Ghiotto,
Angelo Valetto,
Emilia Albesiano,
Franco Fais,
Xiao-Jie Yan,
Cristina P. Sison,
Steven L. Allen,
Jonathan Kolitz,
Philip Schulman,
Vincent P. Vinciguerra,
Petra Budde,
Jurgen Frey,
Kanti R. Rai,
Manlio Ferrarini, and
Nicholas Chiorazzi
From the North Shore-Long Island Jewish Research
Institute; the Department of Medicine, North Shore University Hospital;
and the Department of Medicine, New York University School of Medicine,
Manhasset, NY; Facultät für Chemie-Biochemi II,
Universität Bielefeld, Germany; the Department of Medicine, Long
Island Jewish Medical Center, and the Department of Medicine, Albert
Einstein College of Medicine, New Hyde Park, NY; and the Division of
Clinical Immunology, Istituto Nazionale per la Ricerca sul Cancro,
Dipartmento Oncologia Clinica e Sperimentale Universita di Genova,
Genoa, Italy.
B-cell chronic lymphocytic leukemia (B-CLL) is considered an
accumulative disease of antigen-naive CD5+ B lymphocytes
that circulate in the resting state. However, to evaluate the
possibility that B-CLL cells resemble antigen-experienced and activated
B cells, we analyzed the expression of markers of cellular activation
and differentiation on CD5+CD19+ cells from
B-CLL patients and from age-matched healthy donors. The
leukemic cells from all B-CLL patients, including those that lack
significant numbers of V gene mutations, bear the phenotype of
activated B cells based on the overexpression of the activation markers
CD23, CD25, CD69, and CD71 and the underexpression of CD22, Fc
receptor IIb, CD79b, and immunoglobulin D that are
down-regulated by cell triggering and activation. Furthermore, these
leukemic cells resemble antigen-experienced lymphocytes in the
underexpression of molecules that are down-regulated by cell triggering
and in the uniform expression of CD27, an identifier of memory B cells. A comparison of the phenotypes of B-CLL patients with and without immunoglobulin V gene mutations suggests that the 2 subgroups differ
both in specific marker expression (CD69, CD71, CD62 L, CD40, CD39, and
HLA-DR) and in the time since antigenic stimulation, based on the
reciprocal relationship of CD69 and CD71 expression. These findings
imply that the leukemic cells from all B-CLL cases (irrespective of V
gene mutations) exhibit features of activated and of
antigen-experienced B lymphocytes and that the B-CLL cells that differ
in immunoglobulin V genotype may have different antigen-encounter histories.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Letter in Blood Online:
-
Expression of Fc
receptors type II (Fc RII) in chronic lymphocytic leukemia B cells
- Romina Gamberale, Jorge R. Geffner, Julieta Sanjurjo, Paula X. Fernandez-Calotti, Guillermo Arrosagaray, Julio Sanchez Avalos, and Mirta Giordano
Blood 2003 102: 2698-2699.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
F. J. Li, S. Ding, J. Pan, M. A. Shakhmatov, E. Kashentseva, J. Wu, Y. Li, S.-j. Soong, N. Chiorazzi, and R. S. Davis
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia
Blood,
July 1, 2008;
112(1):
179 - 187.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lanemo Myhrinder, E. Hellqvist, E. Sidorova, A. Soderberg, H. Baxendale, C. Dahle, K. Willander, G. Tobin, E. Backman, O. Soderberg, et al.
A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies
Blood,
April 1, 2008;
111(7):
3838 - 3848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. F. Widhopf II, C. J. Goldberg, T. L. Toy, L. Z. Rassenti, W. G. Wierda, J. C. Byrd, M. J. Keating, J. G. Gribben, K. R. Rai, and T. J. Kipps
Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3
Blood,
March 15, 2008;
111(6):
3137 - 3144.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Murray, N. Darzentas, A. Hadzidimitriou, G. Tobin, M. Boudjogra, C. Scielzo, N. Laoutaris, K. Karlsson, F. Baran-Marzsak, A. Tsaftaris, et al.
Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis
Blood,
February 1, 2008;
111(3):
1524 - 1533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. N. Damle, S. Temburni, C. Calissano, S. Yancopoulos, T. Banapour, C. Sison, S. L. Allen, K. R. Rai, and N. Chiorazzi
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells
Blood,
November 1, 2007;
110(9):
3352 - 3359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Gary-Gouy, A. Sainz-Perez, J.-B. Marteau, A. Marfaing-Koka, J. Delic, H. Merle-Beral, P. Galanaud, and A. Dalloul
Natural Phosphorylation of CD5 in Chronic Lymphocytic Leukemia B Cells and Analysis of CD5-Regulated Genes in a B Cell Line Suggest a Role for CD5 in Malignant Phenotype
J. Immunol.,
October 1, 2007;
179(7):
4335 - 4344.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ian Mockridge, K. N. Potter, I. Wheatley, L. A. Neville, G. Packham, and F. K. Stevenson
Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status
Blood,
May 15, 2007;
109(10):
4424 - 4431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Volkheimer, J. B. Weinberg, B. E. Beasley, J. F. Whitesides, J. P. Gockerman, J. O. Moore, G. Kelsoe, B. K. Goodman, and M. C. Levesque
Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversification
Blood,
February 15, 2007;
109(4):
1559 - 1567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Stamatopoulos, C. Belessi, C. Moreno, M. Boudjograh, G. Guida, T. Smilevska, L. Belhoul, S. Stella, N. Stavroyianni, M. Crespo, et al.
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations
Blood,
January 1, 2007;
109(1):
259 - 270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Deaglio, T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi
In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia
Blood,
August 15, 2006;
108(4):
1135 - 1144.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. I. Del Principe, G. Del Poeta, F. Buccisano, L. Maurillo, A. Venditti, A. Zucchetto, R. Marini, P. Niscola, M. A. I. Consalvo, C. Mazzone, et al.
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia
Blood,
August 1, 2006;
108(3):
853 - 861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Richardson, C. Matthews, M. A. Catherwood, H. D. Alexander, B. S. Carey, J. Farrugia, A. Gardiner, S. Mould, D. Oscier, J. A. Copplestone, et al.
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)
Blood,
May 1, 2006;
107(9):
3584 - 3592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. N. Potter, C. I. Mockridge, L. Neville, I. Wheatley, M. Schenk, J. Orchard, A. S. Duncombe, G. Packham, and F. K. Stevenson
Structural and Functional Features of the B-Cell Receptor in IgG-Positive Chronic Lymphocytic Leukemia.
Clin. Cancer Res.,
March 15, 2006;
12(6):
1672 - 1679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Chiorazzi and M. Ferrarini
Evolving View of the In-Vivo Kinetics of Chronic Lymphocytic Leukemia B Cells
Hematology,
January 1, 2006;
2006(1):
273 - 278.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Stamatopoulos, C. Belessi, A. Hadzidimitriou, T. Smilevska, E. Kalagiakou, K. Hatzi, N. Stavroyianni, A. Athanasiadou, A. Tsompanakou, T. Papadaki, et al.
Immunoglobulin light chain repertoire in chronic lymphocytic leukemia
Blood,
November 15, 2005;
106(10):
3575 - 3583.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Allsup, A. S. Kamiguti, K. Lin, P. D. Sherrington, Z. Matrai, J. R. Slupsky, J. C. Cawley, and M. Zuzel
B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia
Cancer Res.,
August 15, 2005;
65(16):
7328 - 7337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Wiestner
More ZAP for chronic lymphocytic leukemia (CLL)
Blood,
March 1, 2005;
105(5):
1839 - 1840.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Chiorazzi, K. R. Rai, and M. Ferrarini
Chronic Lymphocytic Leukemia
N. Engl. J. Med.,
February 24, 2005;
352(8):
804 - 815.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. T. Messmer, E. Albesiano, D. Messmer, and N. Chiorazzi
The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process
Blood,
May 1, 2004;
103(9):
3490 - 3495.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Tiwari, K. Felekkis, E.-Y. Moon, A. Flies, D. H. Sherr, and A. Lerner
Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis
Blood,
April 1, 2004;
103(7):
2661 - 2667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Ghia, G. Prato, C. Scielzo, S. Stella, M. Geuna, G. Guida, and F. Caligaris-Cappio
Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly
Blood,
March 15, 2004;
103(6):
2337 - 2342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Caligaris-Cappio
The cycling history of CLL
Blood,
January 15, 2004;
103(2):
367 - 367.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. N. Damle, F. M. Batliwalla, F. Ghiotto, A. Valetto, E. Albesiano, C. Sison, S. L. Allen, J. Kolitz, V. P. Vinciguerra, P. Kudalkar, et al.
Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations
Blood,
January 15, 2004;
103(2):
375 - 382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Kern, J.-F. Cornuel, C. Billard, R. Tang, D. Rouillard, V. Stenou, T. Defrance, F. Ajchenbaum-Cymbalista, P.-Y. Simonin, S. Feldblum, et al.
Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway
Blood,
January 15, 2004;
103(2):
679 - 688.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Gamberale, J. R. Geffner, J. Sanjurjo, P. X. Fernandez-Calotti, G. Arrosagaray, J. S. Avalos, and M. Giordano
Expression of Fc{gamma} receptors type II (Fc{gamma}RII) in chronic lymphocytic leukemia B cells
Blood,
October 1, 2003;
102(7):
2698 - 2699.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. McCarthy, W. G. Wierda, L. L. Barron, C. C. Cromwell, J. Wang, K. R. Coombes, R. Rangel, K. S. J. Elenitoba-Johnson, M. J. Keating, and L. V. Abruzzo
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia
Blood,
June 15, 2003;
101(12):
4903 - 4908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Wiestner, A. Rosenwald, T. S. Barry, G. Wright, R. E. Davis, S. E. Henrickson, H. Zhao, R. E. Ibbotson, J. A. Orchard, Z. Davis, et al.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
Blood,
June 15, 2003;
101(12):
4944 - 4951.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E.-Y. Moon and A. Lerner
PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A
Blood,
May 15, 2003;
101(10):
4122 - 4130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. F. Jelinek, R. C. Tschumper, G. A. Stolovitzky, S. J. Iturria, Y. Tu, J. Lepre, N. Shah, and N. E. Kay
Identification of a Global Gene Expression Signature of B-Chronic Lymphocytic Leukemia
Mol. Cancer Res.,
March 1, 2003;
1(5):
346 - 361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps
Biology and Treatment of Chronic Lymphocytic Leukemia
Hematology,
January 1, 2003;
2003(1):
153 - 175.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cerutti, H. Zan, E. C. Kim, S. Shah, E. J. Schattner, A. Schaffer, and P. Casali
Ongoing In Vivo Immunoglobulin Class Switch DNA Recombination in Chronic Lymphocytic Leukemia B Cells
J. Immunol.,
December 1, 2002;
169(11):
6594 - 6603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gurrieri, P. McGuire, H. Zan, X.-J. Yan, A. Cerutti, E. Albesiano, S. L. Allen, V. Vinciguerra, K. R. Rai, M. Ferrarini, et al.
Chronic Lymphocytic Leukemia B Cells Can Undergo Somatic Hypermutation and Intraclonal Immunoglobulin VHDJH Gene Diversification
J. Exp. Med.,
September 2, 2002;
196(5):
629 - 639.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. E. Kay, T. J. Hamblin, D. F. Jelinek, G. W. Dewald, J. C. Byrd, S. Farag, M. Lucas, and T. Lin
Chronic Lymphocytic Leukemia
Hematology,
January 1, 2002;
2002(1):
193 - 213.
[Abstract]
[Full Text]
|
 |
|
| |